This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to Remicade in subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01936181?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
